CNA Finance

About the Author CNA Finance

CNA Finance is a leading finance and investing website that offers content from contributors around the world. Focusing heavily on stock market commentary, market analysis, and investing tips; it's a great place to find articles about all things finance! Joshua’s likes to discuss where assets will move in the market, what reports may be coming out and what to expect, economic conditions and more.

Biotech Beat: Gilead Sciences, Inc. (GILD), Synergy Pharmaceuticals Inc (SGYP), Omeros Corporation (OMER), AVEO Pharmaceuticals, Inc. (AVEO)

I’ve been saying this all year. Ultimately, Gilead Sciences, Inc. (NASDAQ:GILD) has proven to be an incredible stock. Although investors were concerned about the HCV franchise when AbbVie stepped in, those concerns proved to be null when the company released its earnings report. Ultimately, GILD is still the leader with regard to HCV treatments, has received regulatory approval in Japan, and has an incredible record for beating earnings expectations. So, if it’s not in your portfolio already, you may want to strongly consider adding it!

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) is unfortunately continuing down a bearish trend. At this point, it seems as though the bears simply can’t let go of earnings. While SGYP did miss earnings, I wrote a post earlier today discussing why earnings really don’t matter at this point. Ultimately, SGYP is still in clinical stages and hasn’t had a product approved quite yet. Nonetheless, the company has produced incredibly solid data and is turning into a prime candidate for an acquisition. Overall, there are many reasons to be bullish on SGYP and only one to be bearish. With that said, I’m expecting a reversal in the momentum on the stock when either a bigger player in biotech decides to acquire the company or SGYP submits its NDA for plecanatide. So, the declines we’re seeing are only opening the door to getting in on gains at a discount.

Omeros Corporation (NASDAQ:OMER) was having an absolutely incredible day in the market today after announcing positive data from its phase 2 study of OMS721. The treatment is designed to combat thrombotic microangiopathies; a rare group of life-threatening clotting disorders. The data released today showed that two patients demonstrated a 47% increase in mean platelet count and an 86% decrease in red blood cell fragmentation. Ultimately, the positive news led to an incredibly bullish run. While we’re likely to see declines tomorrow, this stock is also likely to generate great opportunities for gains moving forward.

Finally, AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) had an incredible day in the market yesterday; gaining more than 50% by mid-day. However, the story seems to be quite a bit different today. Nonetheless, the bulls really aren’t concerned. As I’ve mentioned several times in the past, price movements in the market tend to happen through a series of overreactions; and that’s exactly what is causing the declines. Investors overreacted yesterday which pushed AVEO higher than it should have been. So today, we’re seeing a correction that’s bringing the stock down to a more sustainable price. Nonetheless, we’re likely to see gains moving forward.

Don’t be late to the party – Click Here to see what 4500 Wall Street Analysts say about your stocks.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts